Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
72.7200
2.5179
1.0461
1.6210
1.1329
4.7021
Low
71.0220
2.6062
No
Yes
No
No
No
No
0.0
No
No
No
No
Dobutamine hydrochloride (CAS No.: 49745-95-1) is a synthetic catecholamine drug widely used in the treatment of cardiovascular diseases, especially playing an important role in acute heart failure and postoperative cardiac support. As a selective β1-adrenergic receptor (β1-AR) agonist, dobutamine hydrochloride can significantly enhance myocardial contractility and increase cardiac output, thereby improving hypoperfusion and tissue ischemia. Its effect on α1-AR and β2-AR is relatively weak, giving it better cardiac selectivity and lower vasoconstrictive side effects.
Although dobutamine hydrochloride is a synthetic product, its structure and function mimic natural catecholamide substances, reflecting the combination of natural product pharmacology and modern medicinal chemistry. In recent years, with in-depth research into the molecular mechanisms of heart failure, the mechanism of dobutamine hydrochloride and its interactions with various molecular targets have gradually been revealed, providing a theoretical foundation for its clinical application and new drug development. This paper will systematically review the chemical structure and physicochemical properties, pharmacological activity, mechanism of action, druggability evaluation, and its clinical application and future prospects in diseases such as heart failure.
The chemical name of dobutamine hydrochloride is (±)-4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]phenol hydrochloride, with the molecular formula C18H23NO3· HCl, molecular weight 301.3860. Its structure includes a catechol group (3,4-dihydroxyphenyl) and a butylamine side chain with an amino group, exhibiting typical catecholamine molecular characteristics. The hydroxyl groups in the molecule give it high polarity and water solubility, and the hydrochloride form further enhances its water solubility and drug stability.
In terms of physicochemical properties, the LogP value of dobutamine hydrochloride is 2.5179, indicating moderate lipid solubility, which is beneficial for transmembrane absorption but not prone to excessive accumulation in lipid environments. The topological pole surface area (TPSA) was 72.72 Ų, indicating moderate polarity and meeting the penetration requirements of drug molecules to biological membranes. The water solubility is 1.6210 (unspecified, usually in mg/mL or mol/L levels), indicating good solubility in water and facilitating the preparation of injectable formulations. The blood-brain barrier penetration ability is lower, reducing the risk of central nervous system side effects. The hERG channel inhibition test results were negative, indicating a low risk of arrhythmia. The Ames mutagenic test result was 0, indicating that the genotoxicity risk is extremely low and meets safety requirements.
Dobutamine hydrochloride is a fully synthetic catecholamine drug, not directly derived from natural plant extracts. However, its structural inspiration comes from naturally occurring catecholamine substances such as dopamine and adrenaline, which are mainly found in the nervous system and adrenal medulla of mammals. The biosynthetic pathways and structural characteristics of catecholamine natural products provide a theoretical basis for the design of dobutamine hydrochloride.
In the field of natural product pharmacology, catecholamine compounds are typically extracted using methods such as water extraction from plant or animal tissues, alcohol extraction, and liquid-liquid distribution. Although dobutamine hydrochloride is not directly extracted from plants, its synthetic route and structural optimization draw on the chemical properties of natural catecholamines, exemplifying the design of heuristic drugs derived from natural products.
The main pharmacological activity of dobutamine hydrochloride lies in its selective stimulating effect on cardiac β1-adrenergic receptors. By activating β1-AR, dobutamine hydrochloride promotes increased cyclic adenosine phosphate (cAMP) levels within myocardial cells, activates protein kinase A (PKA), enhances calcium influx, and thereby enhances myocardial contractility (positive inotropic effect) and heart rate (positive frequency effect), significantly improving cardiac output.
Compared to dopamine and adrenaline, dobutamine hydrochloride has a weaker agonizing effect on α1-AR, resulting in a milder vasoconstrictive effect, reducing increased peripheral resistance, and improving tissue perfusion. Its effect on β2-AR is also weaker, avoiding excessive vasodilation and hypotension risks.
Both animal experiments and clinical studies have confirmed the efficacy of dobutamine hydrochloride in acute heart failure, cardiac function support after cardiac surgery, and cardiogenic shock. It can quickly improve the heart's pumping function, correct hypoperfusion, and reduce organ ischemic damage. In addition, the regulatory effect of dobutamine hydrochloride on myocardial metabolism has also attracted attention. Some studies suggest it may improve myocardial energy supply by modulating the activity of energy-related enzymes within myocardial cells.
The core mechanism of action of dobutamine hydrochloride is to activate β1-AR, regulate intracellular signal transduction pathways, and enhance myocardial contractility and pump efficiency. β1-AR is a G protein-coupled receptor; upon activation, it promotes adenylate cyclase activity through Gs protein, increases cAMP production, activates PKA, and regulates calcium channels and actin-myosin interactions.
In addition to the classic β1-AR signaling pathway, dobutamine hydrochloride involves multiple molecular targets in heart failure treatment:
AMPK (PRKAA1): As a key regulator of cellular energy metabolism, AMPK modulates the energy balance of cardiomyocytes. Dobutamine hydrochloride may indirectly activate AMPK through β1-AR signaling, promoting cardiomyocyte metabolic adaptation and reducing energy metabolism disorders.
EHMT2 (histone methyltransferase): involved in epigenetic regulation of myocardial cells, affecting myocardial remodeling and fibrosis. The cardioprotective effect of dobutamine hydrochloride may be partially realized by regulating EHMT2-mediated gene expression.
APP (amyloid precursor protein): Research shows that APP is expressed in heart tissue, involved in cellular signaling and stress response. Dobutamine hydrochloride may affect APP-related pathways, modulating myocardial cell survival and function.
PTPN1 (protein tyrosine phosphatase 1B): regulates various signaling pathways, including insulin signaling and cardiomyocyte metabolism. Its regulatory effect may affect the pharmacological effects of dobutamine hydrochloride.
MAOA (Monoamine Oxidase A): Participates in the metabolism of catecholamines, regulates catecholamine levels in the myocardium, and affects heart function.
ESR2 (estrogen receptor β): The expression of estrogen receptors in heart tissue is closely related to myocardial protection. Dobutamine hydrochloride may exert a protective effect by modulating ESR2-mediated signaling.
ABCB1 and ABCG2 (ATP binding box transporters): involved in drug efflux and cardiomyocyte drug tolerance, affecting the pharmacokinetics and intracellular concentration of dobutamine hydrochloride.
ALOX15 (lipoxygenase 15): involved in lipid metabolism and inflammatory responses, may affect myocardial inflammation and fibrosis.
FEN1 (Nuclease 1): Involved in DNA repair and cell proliferation, may play a role in cardiac muscle cell stress responses.
In summary, dobutamine hydrochloride not only exerts cardiac nominal strength through the classic β1-AR signaling pathway, but may also participate in multiple mechanisms such as myocardial metabolism, inflammation, remodeling, and cell survival by regulating various molecular targets, reflecting its complex pharmacological network.
Dobutamine hydrochloride has good druggability and possesses multiple properties favorable for clinical application. Its molecular weight is 301.3860, which complies with the Lipinski rule molecular range. The LogP was 2.5179, indicating moderate lipid solubility, which is beneficial for drug distribution in the body and cell membrane penetration. TPSA is 72.72 Ų, indicating moderate polarity suitable for oral absorption (although intravenous administration is often used clinically).
It has good water solubility, making it easy to prepare water-soluble injectables and meeting the medication needs of emergency and critical care care. The blood-brain barrier has a low penetration ability, reducing the risk of central nervous system side effects. The hERG channel inhibition test was negative, reducing the likelihood of drug-induced arrhythmias. The Ames test showed no mutagenicity, indicating high gene safety.
Pharmacokinetics, dobutamine hydrochloride is administered intravenously, rapidly reaching peak plasma concentrations and acting quickly, making it suitable for short-term treatment of acute heart failure. Its half-life is relatively short, about 2 minutes, and continuous infusion is needed to maintain efficacy. It is mainly metabolized by the liver, and its metabolic products are excreted by the kidneys. Its metabolic pathways mainly involve monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), which metabolize rapidly and reduce accumulation and toxicity risks in the body.
Interactions between drugs and multiple transporters (such as ABCB1, ABCG2) affect their distribution and excretion, suggesting that potential drug interactions should be considered in multi-drug combination therapy.
Dobutamine hydrochloride, as the preferred drug for cardiac function support after acute heart failure and cardiac surgery, has clear clinical efficacy and safety. Its ability to rapidly improve cardiac output and correct hypoperfusion makes it one of the indispensable drugs in intensive care and emergency care.
In the future, as research into the pathological mechanisms of heart failure deepens, the application scope and administration strategies of dobutamine hydrochloride are expected to be further optimized. For example, combining AMPK agonists or anti-inflammatory drugs may enhance its cardioprotective effects, delaying myocardial remodeling and functional deterioration. Precise drug administration strategies based on molecular targets will help improve treatment outcomes and reduce side effects.
Additionally, the structural basis of dobutamine hydrochloride provides a template for the design of novel catecholamine drugs. By improving selectivity, extending half-life, or enhancing pharmacokinetic properties through structural modification, it is expected that safer and more effective cardiac positive inotropic drugs will be developed.
In the context of personalized medicine and pharmacogenomics, research on patient-specific molecular targets and metabolic enzyme polymorphisms will promote personalized dose adjustment and efficacy prediction of dobutamine hydrochloride, improving clinical treatment levels.
Dobutamine hydrochloride, as a synthetic catecholamine drug, has become an important drug for the treatment of heart failure and related heart diseases due to its selective β1-AR agonist action and good druggability. Its pharmacological mechanisms not only cover the classic β1-AR signaling pathway but also involve multiple molecular targets, reflecting a complex drug action network. In the future, by deeply analyzing its molecular mechanisms, optimizing drug design, and individualized application, dobutamine hydrochloride and its derivatives will play a greater role in cardiovascular disease treatment, benefiting more patients.
